Korean study confirms FASENRA safety in Real-World use
NCT ID NCT05091333
First seen Feb 06, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This study looked at the safety and effectiveness of the drug FASENRA in 51 Korean adults with severe eosinophilic asthma or a related condition called EGPA. Researchers tracked side effects and how well the drug controlled symptoms during routine medical care. The goal was to confirm the drug's known safety profile and find any new risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA, EGPA(EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Busan, South Korea
-
Research Site
Gangneung-si, South Korea
-
Research Site
Seoul, South Korea
-
Research Site
Suwon, South Korea
-
Research Site
Ulsan, South Korea
Conditions
Explore the condition pages connected to this study.